Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
The irritable bowel syndrome (IBS) market has experienced slow growth owing to a lack of disease understanding, low rate of patients seeking treatment, and few effective therapies that treat all…
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…
IBS-C is an indication ripe for emerging therapies; only three drugs have a label approval for this disease across the major U.S. and European markets, although many therapies are used off-label…
IBS-C is an indication ripe for emerging therapies; only three drugs have a label approval for this disease across the major U.S. and European markets, although many therapies are used off-label…
IBS-D is a highly prevalent disorder regularly encountered in general practice that is marked by excessive defecation and abdominal pain/discomfort. Currently, its etiology and pathophysiology are…
Crohn’s disease (CD) and ulcerative colitis (UC) are the two gastrointestinal inflammatory disorders that constitute inflammatory bowel disease (IBD), affecting approximately 1.25 million people…
Payer and Physician Perspectives on the Role of New Biologics and Biosimilars for Moderate to Severe Inflammatory Bowel Disease Moderate to severe inflammatory bowel disease (IBD) patients who…
Physicians Would Welcome Therapies Causing Lower Rate of Serious Infections than Remicade, but Will Payers View Such Agents Favorably? Treatment for Crohn’s disease (CD)—a relapsing/remitting…
Physicians Would Welcome Therapies Causing Lower Rate of Serious Infections than Remicade, but Will Payers View Such Agents Favorably? Treatment for Crohn’s disease (CD)—a relapsing/remitting…